Law firms lay down swords in Mesoblast shareholder class actions
Two law firms that filed competing class actions against regenerative medicine company Mesoblast for allegedly misleading shareholders about its Remestemcel-L treatment for COVID-19 complications have agreed to join forces and sidestep a beauty parade.
For information on rights and reprints, contact subscriptions@lawyerly.com.au